178 related articles for article (PubMed ID: 23393267)
21. Cancer anorexia - cachexia syndrome.
Muliawati Y; Haroen H; Rotty LW
Acta Med Indones; 2012 Apr; 44(2):154-62. PubMed ID: 22745148
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
[TBL] [Abstract][Full Text] [Related]
23. Review article: anorexia and cachexia in gastrointestinal cancer.
Ockenga J; Valentini L
Aliment Pharmacol Ther; 2005 Oct; 22(7):583-94. PubMed ID: 16181298
[TBL] [Abstract][Full Text] [Related]
24. Erlotinib in previously treated non-small-cell lung cancer.
Shepherd FA; Rodrigues Pereira J; Ciuleanu T; Tan EH; Hirsh V; Thongprasert S; Campos D; Maoleekoonpiroj S; Smylie M; Martins R; van Kooten M; Dediu M; Findlay B; Tu D; Johnston D; Bezjak A; Clark G; Santabárbara P; Seymour L;
N Engl J Med; 2005 Jul; 353(2):123-32. PubMed ID: 16014882
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss.
Gelhorn HL; Gries KS; Speck RM; Duus EM; Bourne RK; Aggarwal D; Cella D
Qual Life Res; 2019 Jun; 28(6):1641-1653. PubMed ID: 30796591
[TBL] [Abstract][Full Text] [Related]
26. Updates on the pathogenesis of advanced lung cancer-induced cachexia.
Zhu R; Liu Z; Jiao R; Zhang C; Yu Q; Han S; Duan Z
Thorac Cancer; 2019 Jan; 10(1):8-16. PubMed ID: 30461213
[TBL] [Abstract][Full Text] [Related]
27. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
28. More research needed on the treatment of the cancer anorexia/cachexia syndrome.
Baracos VE
J Support Oncol; 2006; 4(10):508-9. PubMed ID: 17136866
[No Abstract] [Full Text] [Related]
29. [Cachexia and Sarcopenia Associated with Lung Cancer].
Tanaka S; Takayama K
Gan To Kagaku Ryoho; 2020 Nov; 47(11):1537-1541. PubMed ID: 33268723
[TBL] [Abstract][Full Text] [Related]
30. Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence.
Carlson JJ
Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):409-16. PubMed ID: 19817524
[TBL] [Abstract][Full Text] [Related]
31. Opportunities for targeting the fatigue-anorexia-cachexia symptom cluster.
Alesi ER; del Fabbro E
Cancer J; 2014; 20(5):325-9. PubMed ID: 25299142
[TBL] [Abstract][Full Text] [Related]
32. Anorexia-cachexia syndrome in pancreatic cancer: recent development in research and management.
Uomo G; Gallucci F; Rabitti PG
JOP; 2006 Mar; 7(2):157-62. PubMed ID: 16525199
[No Abstract] [Full Text] [Related]
33. [Anorexia-cachexia syndrome in lung cancer].
Radzikowska E
Pneumonol Alergol Pol; 2008; 76(5):311-2. PubMed ID: 19003759
[No Abstract] [Full Text] [Related]
34. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
35. FAACT-Anorexia Cachexia Scale: Cutoff Value for Anorexia Diagnosis in Advanced Non-Small Cell Lung Cancer Patients.
Turcott JG; Oñate-Ocaña LF; Soca-Chafre G; Ramírez-Tirado LA; Flores-Estrada D; Zatarain-Barrón ZL; Arrieta O
Nutr Cancer; 2019; 71(3):409-417. PubMed ID: 30273069
[TBL] [Abstract][Full Text] [Related]
36. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
37. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
[TBL] [Abstract][Full Text] [Related]
38. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
[TBL] [Abstract][Full Text] [Related]
39. Clinical and economic review of erlotinib in non-small-cell lung cancer.
Yeung K; Carlson JJ
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):411-23. PubMed ID: 22971028
[TBL] [Abstract][Full Text] [Related]
40. Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer.
LeBlanc TW; Nipp RD; Rushing CN; Samsa GP; Locke SC; Kamal AH; Cella DF; Abernethy AP
J Pain Symptom Manage; 2015 Apr; 49(4):680-9. PubMed ID: 25461669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
